latest-news-headlines Market Intelligence /marketintelligence/en/news-insights/latest-news-headlines/novo-nordisk-oral-diabetes-drug-rybelsus-gets-eu-approval-57914378 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Novo Nordisk oral diabetes drug Rybelsus gets EU approval

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Novo Nordisk oral diabetes drug Rybelsus gets EU approval

SNL Image

Novo Nordisk A/S said the European Commission approved its oral diabetes drug Rybelsus for use in all EU member states and the U.K.

Rybelsus, or oral semaglutide, received marketing authorization for the treatment of adults with insufficiently controlled type 2 diabetes to improve blood sugar control in addition to diet and exercise. Rybelsus is a once-daily diabetes drug in tablet form.

The Bagsvaerd, Denmark-based drugmaker said the approval was supported by 10 clinical trials, dubbed Pioneer, which showed Rybelsus' safety and effectiveness.

The medicine is expected to be launched in the first EU countries in the second half of 2020.

Rybelsus was approved by the U.S. Food and Drug Administration on Sept. 20, 2019.